Effect of caloric restriction with or without n-3 polyunsaturated fatty acids on insulin sensitivity in obese subjects: A randomized placebo controlled trial

BBA Clinical

Volumn 4, Issue , 2015, Pages 7-13

  Razny, Urszula ^a   Kiec Wilk, Beata ^a   Polus, Anna ^a   Goralska, Joanna ^a   Malczewska Malec, Malgorzata ^a   Wnek, Dominika ^a   Zdzienicka, Anna ^a   Gruca, Anna ^a   Childs, Caroline E ^b   Kapusta, Maria ^a   Slowinska Solnica, Krystyna ^a   Calder, Philip C ^b,c   Dembinska Kiec, Aldona ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Caloric restriction; Docosahexaenoic acid; Eicosapentaenoic acid; Insulin resistance; N 3 polyunsaturated fatty acids; Obesity

Indexed keywords

PLACEBO; POLYUNSATURATED FATTY ACID;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MONITORING; BODY COMPOSITION; BODY MASS; CALORIC RESTRICTION; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION AND FOLLOW UP; FEMALE; GAS CHROMATOGRAPHY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

EID: 84931267166     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2015.05.001     Document Type: Article

References (64)

1. Swinburn B.A., Sacks G., Hall K.D., McPherson K., Finegood D.T., Moodie M.L., et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011, 378:804-814.
2. Eckel R.H., York D.A., Rossner S., Hubbard V., Caterson I., St Jeor S.T., et al. American heart association. Prevention conference VII: obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 2004, 110:2968-2975.
3. Poirier P., Giles T.D., Bray G.A., Stern J.S., Pi-Sunyer F.X., Robert H., Eckel R.H. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation 2006, 113:898-918.
4. Cnop M., Vidal J., Hull R.L., Utzschneider K.M., Carr D.B., Schraw T., et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2007, 30(3):677-682.
5. Yabe D., Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation. Prog. Biophys. Mol. Biol. 2011, 107(2):248-256.
6. Karhunen L.J., Juvonen K.R., Huotari A., Purhonen A.K., Herzig K.H. Effect of protein, fat, carbohydrate and fibre on gastrointestinal peptide release in humans. Regul. Pept. 2008, 149:70-78.
7. Drucker D.J. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003, 144:5145-5148.
8. McIntosh C.H., Widenmaier S., Kim S.J. Glucose-dependent insulinotropic polypeptide [gastric inhibitory polypeptide; GIP). Vitam. Horm. 2009, 80:409-471.
9. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142(5):687-698.
10. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 1996, 97(11):2601-2610.
11. Thorsdottir I., Tomasson H., Gunnarsdottir I., Gisladottir E., Kiely M., Parra M.D., et al. Randomized trial of weight-loss-diets for young adults varying in fish and fish oil content. Int. J. Obes.(Lond.) 2007, 31(10):1560-1566.
12. Kidd P.M. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural functional synergies with cell membrane phospholipids. Altern. Med. Rev. 2007, 12(3):207-227.
13. Marik P.E., Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic Review. Clin. Cardiol. 2009, 32(7):365-372.
14. Siddiqui R.A., Harvey K.A., Zaloga G.P. Modulation of enzymatic activities by n-3 polyunsaturated fatty acids to support cardiovascular health. J. Nutr. Biochem. 2008, 19(7):417-437.
15. Calder P.C. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009, 91:791-795.
16. Calder P.C. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot. Essent. Fat. Acids 2008, 79:101-108.
17. Jump D.B. The biochemistry of n-3 polyunsaturated fatty acids. J. Biol. Chem. 2002, 277:8755-8758.
18. Adkins Y., Kelley D.S. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J. Nutr. Biochem. 2010, 21:781-792.
19. Flachs P., Rossmeisl M., Bryhn M., Kopecky J., et al. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin. Sci. 2009, 116:1-16.
20. Mozaffarian D., Lemaitre R.N., King I.B., Song X., Huang H., Sacks F.M., et al. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann. Intern. Med. 2013, 158:515-525.
21. Lombardo Y.B., Chicco A.G. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J. Nutr. Biochem. 2006, 17:1-13.
22. Peyron-Caso E., Fluteau-Nadler S., Kabir M., Guerre-Millo M., Quignard-Boulange A., Slama G., et al. Regulation of glucose transport and transporter 4 [GLUT-4) in muscle and adipocytes of sucrose-fed rats: effects of n-3 poly- and monounsaturated fatty acids. Horm. Metab. Res. 2002, 34:360-366.
23. Bjerregaard P., Pedersen H.S., Mulvad G. The associations of a marine diet with plasma lipids, blood glucose, blood pressure and obesity among the Inuit in Greenland. Eur. J. Clin. Nutr. 2000, 54:732-737.
24. Nakamura T., Azuma A., Kuribayashi T., Sugihara H., Okuda S., Nakagawa M., et al. Serum fatty acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: the kumihama study. Br. J. Nutr. 2003, 89:267-272.
25. Krebs J.D., Browning L.M., McLean N.K., Rothwell J.L., Mishra G.D., Moore C.S., et al. Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int. J. Obes. 2006, 30:1535-1544.
26. Glauber H., Wallace P., Griver K., Brechtel G. Adverse metabolic effect of omega-3 fatty acids in noninsulin-dependent diabetes mellitus. Ann. Intern. Med. 1988, 108:663-668.
27. Bandarra N.M., Palma P., Batista I., Kiely M., Thorsdottir I. Effect of a supplemented diet with canned sardine on the lipid fraction of human plasma and erythrocytes. J. Aquat. Food Prod. Technol. 2002, 11:177-185.
28. Allison D.B., Paultre F., Maggio C., Mezzitis N., Pi-Sunyer F.X. The use of areas under curves in diabetes research. Diabetes Care 1995, 18:245-250.
29. Abdul-Ghani M.A., Tripathy D., DeFronzo R.A. Contributions of -cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006, 29:1130-1139.
30. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
31. Mari A., Pacini G., Murphy E., Ludvik B., Nolan J.J. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001, 24:539-548.
32. Bôas Huguenin G.V., Kimi Uehara S., Nogueira Netto J.F., Gaspar de Moura E., Rosa G., da Fonseca Passos M.C. Short term lowcalorie diet improves insulin sensitivity and metabolic parameters in obese women. Nutr. Hosp. 2014, 30(1):53-59.
33. Thies F., Garry J.M., Yaqoob P., Rerkasem K., Williams J., Shearman C.P., et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003, 361:477-485.
34. Vecka M., Dušejovská M., Stankova B., Zeman M., Vavrova L., Kodydkova J., et al. N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Neuro. Endocrinol. Lett. 2012, 33:87-92.
35. Munro I.A., Garg M.L. Dietary supplementation with n-3 PUFA does not promote weight loss when combined with a very-low-energy diet. Br. J. Nutr. 2012, 108(8):1466-1474.
36. Shearer G.C., Savinova O.V., Harris W.S. Fish oil - how does it reduce plasma Triglycerides?. Biochim. Biophys. Acta 1821, 2012:843-851.
37. Schuchardt J.P., Neubronner J., Block R.C., von Schacky C., Hahn A. Associations between omega-3 index increase and triacylglyceride decrease in subjects with hypertriglyceridemia in response to six month of EPA and DHA supplementation. Prostaglandins Leukot. Essent. Fat. Acids 2014, 91(4):129-134.
38. Feskens E.J., Bowles C.H., Kromhout D. Inverse association between fish intake and risk of glucose intolerance in normoglycemic elderly men and women. Diabetes Care 1991, 14:935-941.
39. Patel P.S., Forouhi N.G., Kuijsten A., Schulze M.B., Van Woudenbergh G.J., Ardanaz E., et al. The prospective association between total and type of fish intake and type 2 diabetes in 8 European countries: EPIC-InterAct study. Am. J. Clin. Nutr. 2012, 95:1445-1453.
40. Zhang M., Picard-Deland E., Marette A. Fish and marine omega-3 polyunsatured fatty acid consumption and incidence of type 2 diabetes: a systematic review and meta-analysis. Int. J. Endocrinol. 2013 Sep 8, 2013:501015. 10.1155/2013/501015.
41. Virtanen J.K., Mursu J., Voutilainen S., Uusitupa M., Tuomainen T.P. Serum omega-3 polyunsaturated fatty acids and risk of incident type 2 diabetes in men: the Kuopio ischaemic heart disease risk factor study. Diabetes Care 2014, 37:189-1896.
42. Schectman G., Kaul S., Kissebah A.H. Effect of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes 1988, 37:1567-1573.
43. Zambon S., Friday K.E., Childs M.T., Fujimoto W.Y., Bierman E.L., Ensinck J.W. Effect of glyburide and v3 fatty acid dietary supplements on glucose and lipid metabolism in patients with noninsulin- dependent diabetes mellitus. Am. J. Clin. Nutr. 1992, 56:447-454.
44. Tripathy D., Almgren P., Tuomi T., Groop L. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 2004, 27(9):2204-2210.
45. Stubbs R.S., Wickremesekera S.K. Insulin resistance in the severely obese and links with metabolic co-morbidities. Obes. Surg. 2002, 12(3):343-348.
46. Jimenez-Gomez Y., Cruz-Teno C., Rangel-Zuñiga O.A., Peinado J.R., Perez-Martinez P., Delgado-Lista J., et al. Effect of dietary fat modification on subcutaneous white adipose tissue insulin sensitivity in patients with metabolic syndrome. Mol. Nutr. Food Res. 2014, 58(11):2177-2188.
47. Calder P.C., Yaqoob P. Omega-3 [n-3) fatty acids, cardiovascular disease and stability of atherosclerotic plaques. Cell. Mol. Biol. [Noisy-le-grand) 2010, 56:28-37.
48. Itariu B.K., Zeyda M., Hochbrugger E.E., Neuhofer A., Prager G., Schindler K., et al. Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am. J. Clin. Nutr. 2012, 96:1137-1149.
49. Maedler K., Oberholzer J., Bucher P., Spinas G.A., Donath M.Y. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 2003, 52:726-733.
50. Flachs P., Rossmeisl M., Kopecky J. The effect of n-3 fatty acids on glucose homeostasis and insulin sensitivity. Physiol. Res. 2014, 63:93-118.
51. Nasteska D., Harada N., Suzuki K., Yamane S., Hamasaki A., Joo E., et al. Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes 2014, 63(7):2332-2343.
52. Flatt P.R., Bailey C.J., Kwasowski P., Page T., Marks V. Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic [ob/ob) mice. J. Endourol. 1984, 101:249-256.
53. Calanna S., Urbano F., Piro S., Laferrère B., Gluud L.L., Vilsbøll T., et al. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in metabolic syndrome. Eur. J. Endocrinol. 2012, 166(5):917-922.
54. Vilsboll T., Krarup T., Sonne J., Madsbad S., Volund A., Juul A.G., et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2003, 88:2706-2713.
55. Vollmer K., Holst J.J., Baller B., Ellrichmann M., Nauck M.A., Schmidt W.E., et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008, 57:678-687.
56. Chia C.W., Odetunde J.O., Kim W., Carlson O.D., Ferrucci L., Egan J.M. GIP contributes to islet trihormonal abnormalities in type 2 diabetes. J. Clin. Endocrinol. Metab. 2014, 99(7):2477-2485.
57. Ceperuelo-Mallafré V., Duran X., Pachón G., Roche K., Garrido-Sánchez L., Vilarrasa N., et al. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J. Clin. Endocrinol. Metab. 2014, 99(5):908-919.
58. Yip R.G., Boylan M.O., Kieffer T.J., Wolfe M.M. Functional GIP receptors are present on adipocytes. Endocrinology 1998, 139:4004-4007.
59. Weaver R.E., Donnelly D., Wabitsch M., Grant P.J., Balmforth A.J. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model. Int. J. Obes. [Lond) 2008, (32):1705-1711.
60. Kim S.J., Nian C., McIntosh C.H. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J. Biol. Chem 2007, 282:8557-8567.
61. Getty-Kaushik L., Song D.H., Boylan M.O., Corkey B.E., Wolfe M.M. Glucose-Dependent Insulinotropic Polypeptide Modulates Adipocyte Lipolysis and Reesterification. Obesity (Silver Spring) 2006, 14:1124-1131.
62. Hauner H., Glatting G., Kaminska D., Pfeiffer E.F. Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. Ann. Nutr. Metab. 1988, 32:282-288.
63. McIntosh C.H., Bremsak I., Lynn F.C. Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin. Endocrinology 1999, 140:398-404.
64. Alssema M., Rijkelijkhuizen J.M., Holst J.J., Teerlink T., Scheffer P.G., Eekhoff E.M., et al. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. Eur. J. Endocrinol. 2013, 169(4):421-430.